Generic Paxil Suicide Lawsuit

Citizens Commission on Human Rights Award Recipient (Twice)
Humanist, humorist

Monday, March 19, 2007

Suicide attempts in clinical trials with paroxetine randomised against placebo

Before continuing to read the results let me just remind you of a few of the statements that has come from GSK and the MHRA regarding suicide and Seroxat:

Dr ALASTAIR BENBOW Head of European Psychiatry , GlaxoSmithKline
The evidence, however, is clear, these medicines are not linked with suicide, these medicines are not linked with an increased rate of self harm

Dr ALISTAIR BENBOW Head of European Clinical Psychiatry GlaxoSmithKline
We have been asked by the regulatory authorities to provide all our information related to suicides and I can tell you the data that we provide to them clearly shows no link between Seroxat and an increased risk of suicide – no link.

There is very good clinical trial evidence that these drugs do not cause suicide, they do not cause suicidal thoughts in adults. There is a very large database.

GlaxoSmithKline, which earned £100 million last year from UK sales of Seroxat, has always denied there was "compelling evidence" linking SSRIs with suicide.

Alan Metz, GSK North American medical director told the Wall Street Journal: “Each time it hs been looked at, there is no suggestion of an association with suicidal tendencies in adults

Professor Kent Woods Chief Executive MHRA
In relation to the use of SSRIs in young adults the Expert Working Group concluded that there is no clear evidence of an increased risk of self-harm and suicidal thoughts in young adults of 18 years or over. However, given that individuals mature at different rates and that young adults are at a higher background risk of suicidal behaviour than older adults, as a precautionary measure young adults treated with SSRIs should be closely monitored. The Group also recommended that in further research on the safety and efficacy of SSRIs, young adults should be assessed separately.

Now bear those statements in mind when you read the following study. If proven to be correct the above people who made those staements and also a plethora of other people from the MHRA, FDA and GSK who have also robustly denied suicidal behaviour should be all prosecuted for crimes against humanity. This is a scandal of epic proportions.

Suicide attempts in clinical trials with paroxetine randomised against placebo



Inclusion of unpublished data on the effects of antidepressants on children has suggested unfavourable risk-benefit profiles for some of the drugs. Recent meta-analyses of studies on adults have indicated similar effects. We obtained unpublished data for paroxetine that have so far not been included in these analyses.


The documentation for drug registration contained 16 studies in which paroxetine had been randomised against placebo. We registered the number of suicides, suicide attempts and ideation. We corrected for duration of medication and placebo treatment and used a standard Bayesian statistical approach with varying priors.


There were 7 suicide attempts in patients on the drug and 1 in a patient on placebo. We found that the probability of increased intensity of suicide attempts per year in adults taking paroxetine was 0.90 with a "pessimistic" prior, and somewhat less with two more neutral priors.


Our findings support the results of recent meta-analyses. Patients and doctors should be warned that the increased suicidal activity observed in children and adolescents taking certain antidepressant drugs may also be present in adults.


The debate about whether the use of antidepressant drugs increases suicidal activity has recently been sharpened after more than 10 years of turmoil [1]. Conclusions concerning children and adolescents have been drawn [2]. Inclusion of unpublished data suggested unfavourable risk-benefit profiles for some of the drugs. For adults, industry points to the absence of data refuting the null hypothesis (no such increase).

In a February 19th BMJ editorial [3] accompanying two meta-analyses of suicidal activities in adult patients on SSRIs [4,5], the authors failed to convey the unanimous conclusion in the reviewed studies of an increased risk of suicidal attempts. Admittedly, one of the analyses only touched statistical significance, but that might have been due to the withholding of data by the manufacturer of one of the drugs. We have had access to some of those missing data. Recently we were given the opportunity to review the clinical data on paroxetine as presented to the world's drug regulatory agencies in 1989. One of the published meta-analyses [4] contained summaries of the documentation provided by the marketing authorization holders to the MHRA, which did not distinguish between suicidal attempt and suicidal ideation for paroxetine. We studied the primary data and even the individual case descriptions when available. Another meta-analysis [5] reported published data only, whereas most of our data were from unpublished studies. Moreover, as opposed to the BMJ authors, we have based our statistical analysis on comparing intensities of suicide attempts per year in drug and placebo groups, taking the exposure time of the patients properly into account. We now present our findings and estimate the degree of support for the idea of an increased intensity per year of suicide attempts in adults.


We included only double blind, parallel design studies with patients (all adults) randomised to either paroxetine or placebo. Altogether 16 studies met these criteria (references 79 to 93 and 95 in the Expert Report), containing respectively 916 and 550 paroxetine and placebo treated patients. The study period was in most instances 6 weeks. One important exception was a study (reference 91) with a preponderance of paroxetine use over placebo and lasting for 17 weeks. Patients were excluded from the studies after a suicide-related event. Taking this censoring into account, paroxetine treatment made up 190.7 patient years altogether and placebo 73.3 patient years. Suicide-related events could be found in tables in the Expert Report, in the adverse reactions section in the individual study reports, and in the individual patient descriptions.

We let θp be the intensity per year of a suicide attempt in the placebo group and θd the intensity per year in the drug group, for a random patient in the 16 studies; correspondingly, Xp and Xd represent the total numbers of suicide attempts. We can have at most one suicide attempt for each patient. Taking this censoring into account, we denoted the corresponding patient years in the 16 studies combined by mp and md. In addition, patients in both the placebo and drug groups are supposed to behave in a similar manner. It then follows that the likelihood of the experiment corresponds to Xp and Xd having Poisson distributions respectively with parameters (mpθp) and (md θd). In addition, we assume that the two variables were conditionally independent given the parameters. The corresponding observed data are (xp, mp) and (xd, md), and the prior information is denoted by (xop, mop) and (xod, mod).

The Bayesian approach is based on the construction of probability distributions for θp and θd . This does not mean that these parameters are to be interpreted as random variables, but our knowledge of the parameters is uncertain and we describe this uncertainty with the help of probability distributions. Probability distributions describing our initial uncertainty are called prior distributions (that is, before real data are collected). When the real data are taken into account, the prior distributions are updated by Bayes' formula to posterior distributions. An excellent introduction to Bayesian methods in medicine is given by Spiegelhalter et al. [6].

We assume that the prior distribution for θp is gamma, with parameters xop and mop, while correspondingly θd has the parameters xod and mod and is assumed to be independent of the prior distribution for θp. Hence, standard Bayesian theory gives the posterior distribution of θp as gamma, with parameters xop + xp and mop + mp, while θd will have the parameters xod + xd and mod + md. We performed simulations by making 80000 random draws of θd and θp from their independent gamma posterior distributions, computed the logarithms of the ratios θd/θp, and constructed diagrams by applying a standard density estimation technique to these logarithms. (The logarithm was introduced to avoid an unwelcome feature of the density estimation method.) Note that the logarithm of the ratio θd/θp is greater than zero whenever θd is greater than θp. Hence, we calculated the probabilities that medication with paroxetine is associated with an increased intensity of a suicide attempt per year as the proportions of logarithmic ratios greater than zero in the samples. This corresponds to areas below the densities to the right of zero in the diagrams.

The grounds for a pessimistic prior have been given by Healy and Whitaker [7] who, relating the occurrence of suicidal activities to the use of antidepressant drugs, estimated an odds ratio of 2.4 from evidence given in clinical trials, epidemiological observations and case histories. The clinical trial data they used included, but were not restricted to, studies with the active drugs randomised against placebo. Mathematically, we chose to express this view as equivalent to observing two (xod) events with paroxetine during 50 (mod) patient years and one (xop) with placebo during 50 (mop) patient years, adding up to 3 attempts per 100 patient years, which is similar to our observed average value for paroxetine and placebo taken together. We based the calculations on a total of only 100 (mod + mop) patient years in the prior, compared to 264 (md + mp) patient years in the real data, in order to increase the importance of the real data over the prior information. The slightly optimistic and slightly pessimistic priors represent respectively a paper by Lapierre [8] (appearing in tandem with Healy and Whitaker) and the article that reported suicidal ideation in children medicated with paroxetine [2]. The former author took the attitude that, if anything, there were slight signs of reduced suicidal activity connected with antidepressants, whereas the latter authors left the reader with the assumption that the observed increased suicidal ideation in children must somehow be reflected in adults. We assigned the numbers of suicidal patients on paroxetine and placebo per 50 patient years to be respectively 1.35 and 1.65 and vice versa.


There were no suicides in the 16 studies with paroxetine randomised against placebo. Suicidal activities are listed in table 1. Summarising the suicide attempts, there are seven among the patients on paroxetine and one among the patients on placebo. (One event tabulated in the Expert Report as occurring with placebo did in fact happen during the run-in period before randomisation.)

The three prior distributions of the logarithm of the ratio θd/θp are shown in figure 1, and the corresponding posterior distributions are shown in figure 2. The probability that medication with paroxetine is associated with an increased intensity per year of a suicide attempt is 0.90 with the pessimistic prior (Healy and Whitaker [7]), and 0.79 (Lapierre [8]) and 0.85 (Whittington et al. [2]) with the two other priors. The corresponding prior probabilities were respectively 0.75, 0.42 and 0.58.


We believe that the chosen studies are similar enough to be pooled for analysis. This view is supported by the similarities of the protocols for the various studies, although the populations that were studied differed considerably. We also believe it is best to count patient years rather than patients, although claims have been made for the contrary [7]. At least, counting patient years is a more conservative approach. Furthermore, to treat the patient as a unit and to assume binomial distributions would be inappropriate since patients have different follow-up times and hence different probabilities of suicide attempts within both the placebo and the drug groups.

Another statistical approach would have been to express the prior distributions in terms of independent priors for θp and the ratio θd/θp, with a common, relatively weak prior for θp in all three formulations. This was our approach in a previous publication using basically the same method [9]. To make things simpler and perhaps more transparent in this short paper, we have not used this approach here.


Although we report a small data set, by taking various priors into account the data strongly suggest that the use of SSRIs is connected with an increased intensity of suicide attempts per year. The two meta-analyses and our contribution taken together make a strong case for the conclusion, at least with a short time perspective, that adults taking antidepressants have an increased risk of suicide attempts. We also conclude that the recommendation of restrictions on the use of paroxetine for children and adolescents recently conveyed by regulatory agencies [10] should be extended to include usage by adults.


1. Breggin PR: Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRI): A review and analysis.
International Journal of Risk and Safety in Medicine 2004, 16:31-49.
Return to citation in text: [1]

2. Whittington CJ, Kendall T, Fonagy O, Cottrell D, Cotgrove A, Boddington E: Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.
Lancet 2004, 363:1341-1345. [PubMed Abstract] [Publisher Full Text]
Return to citation in text: [1] [2] [3]

3. Cipriani A, Barbui C, Geddes JR: Suicide, depression, and antidepressants. Patients and clinicians need to balance benefits and harms.
BMJ 2005, 330:373-374. [PubMed Abstract] [Publisher Full Text]
Return to citation in text: [1]

4. Gunnell D, Saperia J, Ashby D: Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review.
BMJ 2005, 330:385-388. [PubMed Abstract] [Publisher Full Text] [PubMed Central Full Text]
Return to citation in text: [1] [2]

5. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B: Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials.
BMJ 2005, 330:396-399. [PubMed Abstract] [Publisher Full Text] [PubMed Central Full Text]
Return to citation in text: [1] [2]

6. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR: An introduction to Bayesian methods in health technology assessment.
BMJ 1999, 319:508-512. [PubMed Abstract] [Publisher Full Text]
Return to citation in text: [1]

7. Healy D, Whitaker C: Antidepressants and suicide: risk-benefit conundrums.
J Psychiatry Neurosc 2003, 28:331-337. [PubMed Abstract] [Publisher Full Text] [PubMed Central Full Text]
Return to citation in text: [1] [2] [3]

8. Lapierre YD: Suicidality with selective serotonin reuptake inhibitors: Valid claim?
J Psychiatry Neurosci 2003, 28:340-347. [PubMed Abstract] [Publisher Full Text] [PubMed Central Full Text]
Return to citation in text: [1] [2]

9. Aursnes I, Tvete IF, Gaasemyr J, Natvig B: Clinical efficacies of antihypertensive drugs.
Scand Cardiovasc J 2003, 37:72-79. [PubMed Abstract] [Publisher Full Text]
Return to citation in text: [1] [2]

10. FDA issues public health advisory on cautions for use of antidepressants in adults and children
Return to citation in text: [1]

Pre-publication history

The pre-publication history for this paper can be accessed here:

No comments:

Please contact me if you would like a guest post considered for publication on my blog.